PTC Therapeutics stockholders approve routine annual meeting matters

Filed June 5, 2026 · Period ending June 2, 2026 · ~1 min read

Key Changes

• low

  Four Class I directors elected to three-year terms through 2029: Jessica Chutter, Matthew B. Klein, Stephanie S. Okey, and Jerome B. Zeldis, all receiving majority support.

  Item 5.07 verify on EDGAR →
• low

  Ernst & Young LLP ratified as independent auditor for fiscal 2026 with 99.5% approval, maintaining continuity in external audit relationship.

  Item 5.07 verify on EDGAR →
• low

  Executive compensation approved in non-binding say-on-pay vote with 97.9% support, indicating strong stockholder backing of management pay practices.

  Item 5.07 verify on EDGAR →